PRESS RELEASE

Nanoform awarded with a Seal of Excellence from the European Commission

Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project. The award certifies that the proposal is of a high quality with an exceptional degree of innovation and impact.

The “Nanomedicines of Tomorrow” project applies proprietary nanonization technology to reduce rates of clinical attrition through improved drug solubility and bioavailability. Nanoform’s nanoparticle engineering technology will significantly increase the number of drugs reaching the market, with patients around the world benefiting from the development of more efficient treatments.

The Seal of Excellence is an initiative that began in 2015 to provide validation for proposals that have reached the stringent threshold for Horizon 2020. The project was evaluated by an international panel of independent experts to ensure that the rigorous assessment criteria of excellence, impact, quality and efficiency of implementation were met

Edward Hæggström, CEO of Nanoform said: “We are delighted that our proposal has been endorsed by the European Commission. Receiving the Seal of Excellence has reinforced our commitment to helping companies around the world find ground-breaking solutions to their complex drug development challenges.”

Notes to the Editor

For further information, images and interview opportunities with Nanoform, please contact:
Pranika Sivakumar at Notch Communications
Pranika.sivakumar@notchcommunications.co.uk
+44 (0) 161 457 7230

About Nanoform

Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.

For more information please visit http://www.nanoform.fi/